Related Experiment Video
Updated: Mar 2, 2026

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes
Published on: December 16, 2022
Structural and electrophysiological dysfunctions due to increased endoplasmic reticulum stress in a long-term pacing
Chang Cui1, Le Geng1, Jiaojiao Shi1
1Division of Cardiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China.
Insights
Long-term ventricular pacing causes heart dysfunction by increasing ER stress and calpain. Inhibiting calpain may offer a new therapeutic target for patients with pacemakers.
Area of Science:
- Cardiology
- Biomedical Engineering
- Stem Cell Biology
Background:
- Long-term ventricular pacing can harm heart function, especially when cumulative percent ventricular pacing (Cum%VP) exceeds 40%.
- The cellular mechanisms linking pacing to myocardial disorders are not fully understood.
- Existing research is limited by the difficulty of obtaining human cardiac tissue and the lack of long-term in vitro pacing models.
Purpose of the Study:
- To investigate the cellular disturbances and molecular pathways underlying pacing-induced myocardial dysfunction.
- To establish and utilize a novel in vitro model for studying long-term cardiac pacing effects.
Main Methods:
- Human induced pluripotent stem cell-derived ventricular cardiomyocytes (VCMs) were subjected to electrical stimulation for 2 weeks.
- Quantitative structural and electrophysiological analyses were performed to assess pacing-induced changes.
Main Results:
- Paced VCMs showed reduced contractile protein expression, increased apoptosis, and electrophysiological remodeling in a Cum%VP-dependent manner.
- Long-term pacing activated both endoplasmic reticulum (ER) stress and calpain.
- Calpain inhibition mitigated adverse structural remodeling and improved ICa, L in paced VCMs.
Conclusions:
- Two weeks of in vitro pacing induced structural and electrophysiological dysfunction in VCMs.
- Increased ER stress and calpain activation appear to be central mechanisms in pacing-induced heart disease.
- Targeting calpain may represent a novel therapeutic strategy for managing patients with long-term ventricular pacing.
Background:
Long-term ventricular pacing has deleterious effects and becomes more significant when cumulative percent ventricular pacing (Cum%VP) exceeds 40% of time. However, cellular disturbances and pathways by which pacing leads to myocardial disorders are not well understood. Attempts to resolve these questions have been hampered by difficulties in obtaining human cardiac tissue and the inability to build a longer-lasting (lasting longer than weeks) pacing model in vitro.
Methods:
Human induced pluripotent stem cell-derived ventricular cardiomyocytes (VCMs) were cultured in the presence of electrical stimulation for 2 weeks. Quantitative structural and electrophysiological analyses were used to define the functional disturbances of pacing.
Results:
Compared to controls, paced VCMs exhibited a remarkable reduction in the contractile protein expression, an increased apoptosis ratio and electrophysiological remodelling in a Cum%VP-dependent manner. Investigation of the protein expression levels revealed that long-term pacing universally activated both ER stress and downstream calpain. Moreover, the inhibition of calpain attenuated the adverse effects on the structural remodelling and increased the ICa, L in paced VCMs.
Conclusions:
The results demonstrated that pacing VCMs for 2 weeks in vitro led to a series of structural and electrophysiological dysfunctions. The increased ER stress and downstream calpain could be a central mechanism underlying the disease pathogenesis. This finding could represent a new therapeutic target in the management of long-term pacing patients.
More Related Videos
11:13Electrophysiological Analysis of human Pluripotent Stem Cell-derived Cardiomyocytes hPSC-CMs Using Multi-electrode Arrays MEAs
Published on: May 12, 2017
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023